ÉúÎïѧ½¹Óò,biological focal regionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ïà¶ÔÉúÎïѧЧӦ,Relative biological effectivenessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¬ÉùÈÈÁÆ,ultrasound hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PPS³éÑù,PPS samplingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CdSÁ¿×Óµã,CdS quantum dotsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔöÖ³ÓëµòÍö,Proliferation and apoptosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °¢¿ËÀ­Ã¹ËØA,Aclacinomycin AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ԭʼÉñ¾­ÍâÅßÒ¶Áö,primitive neuroectodermal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇСϸ°û,non-small cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ÚÂÉ»¯ÁÆ,Metronomic chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÄÍÒ©,Drug resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇÕÛµþµ°°×·´Ó¦,unfolded protein responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û¹ý¼ÌÃâÒßÖÎÁÆ,Adoptive cellular immunotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« תÒÆÁܰͽá,metastatic lymph nodesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯¿éÅàÑø,explant cultureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »îÔØÌåÒßÃç,live vector vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­Æ¤ÉöÔìðüÊõ,Percutaneous nephrostomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÅÏ¢´«µ¼,Signal transductionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×¹¹Ïó,protein conformationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÉú³¤ÇúÏß,Cell growth curveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÅÐÔÄÉÃײÄÁÏ,magnetic nanomaterialsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈȲÎÊý,thermal parameterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢ÐÍÓлúºÏ³É,microscale organic synthesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Õæ¿Õ´ü,vacuum bagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Ã-°±»ù¶¡ËáÊÜÌå,GABA receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Îϸ°ûÐԸΰ©,Hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©Ö¢·ÖÀà,cancer classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÏËά×é֯ϸ°ûÁö,Malignant fibrous histiocytomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ì岿Ö×Áö,body tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î°©Ò׸ÐÐÔ,lung cancer susceptibilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±ÊÐÎÊø,pencil beamÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˶ËÁ£Ã¸Äæת¼øÆô¶¯×Ó,hTERT promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇÖÏ®ÐÔÏËάÁö²¡,Aggressive fibromatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉäƵÈÈÁÆ,Radiofrequency hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ºÔ­¢ôÐÍ,collagen type ¢ôÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉúÎï¼î²¿Î»,alkaloid fractionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔ¸¹Ç»»ýÒº,malignant ascitesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TP·½°¸,TP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éµ°°×¼×»ùתÒÆø,histone methyltransferaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÒ¶¹âÕ¤,multileaf collimatorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÈÏûÈÚ,Thermal ablationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« L-929ϸ°û,L-929 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔàÆ÷¹¦ÄÜ,Organ functionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­°©»ùÒòµ°°×ÖÊc-mdm2,Proto-oncogene proteins c-mdm2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØÀë×ÓÖΰ©,heavy-ion cancer therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖܼÁÁ¿,weekly doseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÈܽâ×ÛºÏÕ÷,Tumor lysis syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÍ´øÑùÐÍÏËάÁö²¡,desmoid-type fibromatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« С¼ÁÁ¿»¯ÁÆ,Low dose chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Ö²¿¶¾ÐÔ,local toxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇËè΢תÒÆ,Bone marrow micrometastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¥´¿ðåÕ¶¾ÐØÜÕ¼¤Ã¸»ùÒò,Herpes simplex virus thymidine kinase geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȾɫÌå²»Îȶ¨,chromosomal instabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×Á×Ëáø2C,Protein phosphatase 2CÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©ÒßÃç,cancer vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½Ç¶ÈÓÅ»¯,angle optimizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒìÁòÇèËáÜÐõ¥,benzyl isothiocyanateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉúÎï¶àÌÇ,biological polysaccharideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂÈ»¯¸ÆÈÜÒº,CaCl_2 solutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ü°²Ã¸ÁªÃâÒß·ÖÎö,voltammetric enzyme-linked immunoassayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÓζС²ñºúÌÀ,Modified Minor Radix Bupleuri DecoctionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇÖÏ®ÐÔÏËάÁö,aggressive fibromatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« N-ras»ùÒò,N-ras oncogeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÙÏËάÔöÉúÐÔСԲϸ°ûÖ×Áö,desmoplastic small round cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EC9706,EC9706 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò½ÓûúÆ÷ÈË,Medical RobotÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÎÁƼƻ®ÏµÍ³,treatment planning systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °ÐÇø¹´»­,Target delineationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂËÅÝÊ÷ͻ״ϸ°û,follicular dendritic cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýάÊÊÐÎ,Three-dimensional conformalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÐÓ¦¼ÓÎÂ,Inductive heatingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÖÎÓú,tomor rejectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±í¹ÛÒÅ´«Ñ§µ÷¿Ø,epigenetic regulationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EphÊÜÌå,Eph receptorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾«È··ÅÁÆ,precise radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áöɸ²é,tumor screeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇÖ×Áö/¼Ì·¢ÐÔ,Bone Neoplasms/secondaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Rb94»ùÒò,Rb94 GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒÖÖÆÒò×Ó,Tumor suppressorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ß¼ÁÁ¿ÂÊ,High dose rateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÈéÍ·×´Áö²¡¶¾16ÐÍ,Human papillomavirus type 16Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ïû¼«°²ÀÖËÀ,passive euthanasiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔ/Ò©ÎïÁÆ·¨,malignant/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÛÍ´»º½â,Pain reliefÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪÇå·´Ó¦Òò×Ó,Serum response factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Á-ÉúÓý·ÓçúçêËáõ¥,¦Á-Tocopheryl succinateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µç×ÓÉäÒ°Ó°Ïñϵͳ,Electronic portal imaging deviceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÏµÍ³¸±Ö×Áö×ÛºÏÕ÷,paraneoplastic syndrome of nervous systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʹÓ÷ÖÎö,analysis of useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« von Hippel-Lindau×ÛºÏÕ÷,von Hippel-Lindau syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÜЧÒò×Ó,Energy efficiency factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇתÒÆÌÛÍ´,metastatic bone painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« GAGE»ùÒò,GAGE GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍâÖÜѪDNA,peripheral blood DNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö½þÈóÊ÷ͻ״ϸ°û,tumor infiltrating dendritic cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇàÝïËØÑÜÉúÎï,artemisinin derivativesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÐÎÐÔ½ºÖÊĸϸ°ûÁö,Glioblastoma multiformeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅÁÃ×Á×Ëá¶þÄÆ,Pamidronate disodiumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÇ»ÄÚ»¯ÁÆ,intrapleural chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èý½×ÌÝֹʹ,three-step analgesic ladderÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 ÉÏÒ»Ò³ 4 5 6 7 8 9 10 11 ÉÏÒ»Ò³